ABIONYX Pharma Announces Its 2023 Full-Year Financial Results

Regulatory News:

ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, today announced its 2023 full-year financial results as approved by the full Board of Directors and an update on the activity to date. The audit procedures on the consolidated financial statements have been completed. The certification report has not yet been issued. It will be issued once the procedures required for filing the universal registration document will be completed.

Selected financial information
(as of December 31, 2023/Consolidated financial statements under IFRS)

M€	2023	2022
Revenues	4.6	5.3
Cost of goods and services sold	(4.0)	(4.6)
R&D expenditure	(1.5)	(1.1)
Administrative and commercial expenses	(2.6)	(3.7)
Other income and expenses	0.1	0
Operating Income	(3.4)	(4.1)
Financial income	0.2	0.2
Financial expenses	(0.3)	(0.3)
Financial result	(0.1)	(0.1)
Net income	(3.5)	(4.2)
Net cash flow from operating activities	(3.7)	(3.4)
Net cash used in investing activities	(0.1)	(0.2)
Net cash flow from financing activities	3.9